AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
AZITHROMYCIN USP
8 registrations across 4 African markets— 3 active
Markets with AZITHROMYCIN USP
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| SKAZI 200 Suspension | 🇷🇼Rwanda | S KANT HEALTHCARE LTD | active | Aug 2029 |
| AZIROCIN CAPSULES | 🇬🇭Ghana | — | active | Dec 2027 |
| AZIROCIN CAPSULES | 🇬🇭Ghana | — | active | Dec 2027 |
| AZINOWEL-200 200MG/5ML ORAL SUSPENSION ORAL SUSPENSION | 🇲🇼Malawi | — | expired | Mar 2025 |
| DANTHROMYCI N TABLETS TABLETS/ 1X6 | 🇳🇬Nigeria | ALPHA PHARMACY & STORES 2B | expired | Mar 2022 |
| MAYGLOW AZITHROMYCIN 500MG TABLETS TABLETS/1 X 1000 | 🇳🇬Nigeria | MAYYGLOW PHARM LTD NO. 14 | expired | Nov 2021 |
| KASIFA ORAL SUSPENSION POWDER /1X30ML | 🇳🇬Nigeria | MEDICROWN NIG LTD 7 | expired | Apr 2021 |
| KASIFA TABLETS TABLETS/1X10 | 🇳🇬Nigeria | MEDICROWN NIG LTD 7 | expired | Apr 2021 |
AZITHROMYCIN USP in Africa — Regulatory Overview
AZITHROMYCIN USP is registered across 4 African markets with 8 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Nigeria, Ghana, Malawi, Rwanda. AfricaRegulatory refreshes this data daily from official government sources.
Of the 8 registrations, 3 (38%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.